"A novel dual-pathway inhibitor of tumor angiogenesis passed a preliminary clinical test, demonstrating manageable toxicity and biomarker evidence of engagement with the drug’s targets, as reported at the 2016 ASCO Annual Meeting in Chicago. “ABT-165 engages and inhibits both DLL4 and VEGF targets/pathways,” said Michael S. Gordon, MD, president and CEO of Pinnacle Oncology Hematology in Scottsdale, Arizona. “ABT-165 is generally well tolerated at single-agent doses up to 3.75 mg/kg. However, long-term consequences of dual DLL4 and VEGF inhibition need to be evaluated. An ongoing phase Ib study is exploring the combination of ABT-165 and chemotherapy in multiple indications amenable to antiangiogenic therapy. - 2 weeks ago via Facebook
"Novel #Angiogenesis Inhibitor Shows Preliminary Evidence of Activity .@ASCO #cancer https://t.co/Hv6D8aZigz https://t.co/AX70wGv8H0 - 2 weeks ago via Twitter
"Drug repurposing of non-cancer drugs represents an attractive approach to develop new cancer therapy. Using the TRAMP transgenic mouse model, glipizide, a widely used drug for type 2 diabetes mellitus, has been identified to suppress prostate cancer (PC) growth and metastasis. Angiogenesis is intimately associated with various human cancer developments. Intriguingly, glipizide significantly reduces microvessel density in PC tumor tissues, while not inhibiting prostate cancer cell proliferation from the MTT assay and flow cytometry investigation. Moreover, glipizide inhibits the tubular structure formation of human umbilical vein endothelial cells by regulating the HMGIY/Angiopoietin-1 signaling pathway. Taken together, these results demonstrate that glipizide has the potential to be repurposed as an effective therapeutic for the treatment of PC by targeting tumor-induced angiogenesis. - 3 weeks ago via Facebook
"EU okays #Avastin / #Tarceva combination for #lungcancer https://t.co/fLCssTaHML #cancer https://t.co/yvgK3oVKkR - 3 weeks ago via Twitter
"Roche has been granted approval in Europe for Avastin in combination with Tarceva for patients with EGFR-positive non-small cell lung cancer (NSCLC). Avastin targets VEGF while Tarceva is an EGFR inhibitor - pathways known to be drivers of tumour growth - and both are already approved individually as NSCLC therapies. The approval is based on the results of a pivotal phase II trial, which showed that giving Avastin alongside Tarceva as a first-line therapy in this patient population reduced the risk of disease progression or death by 46% compared to Tarceva alone. - 3 weeks ago via Facebook
"#Tumors have found a bloody new way to grow and spread .@sciencemagazine .@aaas #cancer https://t.co/1oYuMs8nKT https://t.co/h0KiUcXZom - 3 weeks ago via Twitter
"Vasculogenic mimicry, in which cancer cells themselves form blood-carrying channels, may supplement traditional angiogenesis in supplying nutrients to tumors. Targeting blood vessels built out of the tumor’s own cells may be a new treatment option. - 3 weeks ago via Facebook
"A growing tumor needs access to oxygen and nutrients from the blood, making the development of new blood vessels into the tumor a fundamental aspect of cancer behavior - and one that could be targeted for more effective treatment. Sarah Bohndiek at the University of Cambridge leads an international team using bioimaging techniques to better understand the topic, giving her a broad perspective on the potential for novel photonics technologies to tackle this key question in cancer studies. - 4 weeks ago via Facebook
"Optical imaging reveals vital details of #cancer growth https://t.co/RckoCapGGs .@Cambridge_Uni #WednesdayWisdom https://t.co/rO9njqlwub - 1 month ago via Twitter
"New research in mice reveals that an inhibitor of the Janus kinase 2 (JAK2) protein can shrink triple-negative breast cancer, which lacks expression of the estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2. This cancer is the most lethal form of breast cancer and the only type of breast tumor still lacking a targeted treatment. Preclinical research suggests inhibiting JAK2, a protein involved in cell growth and division, may help shrink triple negative breast cancer tumors. - 1 month ago via Facebook
"Cabozantinib drug can extend lives of patients with advanced renal cell carcinoma https://t.co/04dks3if89 #cancer - 1 month ago via Twitter
"Targeted Therapy Blocks Growth of Triple-Negative #BreastCancer in Mice https://t.co/4mkorDetQq #angiogenesis .@jama_current - 1 month ago via Twitter
"New way to grow #blood vessels in lab for transplantation could boost regenerative #medicine https://t.co/LHgRtBWPUg .@UniofBath #health - 2 months ago via Twitter
"Oscillations determine if #blood vessels grow thicker or branch #cancer #diabetes #endcancer https://t.co/dU5cFz5izx https://t.co/BAmBO8Z6nQ - 2 months ago via Twitter
"Common fish-oil supplement #DHA boosts kidney #cancer therapy https://t.co/OTLCJg3jkE #WednesdayWisdom #cancertrials #endcancer #eattobeat - 2 months ago via Twitter
CAMBRIDGE, Mass., May 11, 2016/PRNewswire/ -- Dr. William Li and musician and activist The Edge of U2, both board members of the non-profit Angiogenes Read More >
The FDA has approved Afinitor (everolimus) for the treatment of adult patients with progressive, well-differentiated non-functional, locally advanced Read More >
Inaugural World Summit on Food and Health in Paris Convened Innovative Thinkers from Science, Medicine, Culinary, Technology, and Aerospace Fields to Read More >
The U. S. Food and Drug Administration approved ramucirumab for use in combination with FOLFIRI for the treatment of patients with metastatic colorect Read More >
Dr. William Li, President and Medical Director of the Angiogenesis Foundation, gave the keynote address at the Read More >
The U.S. Food and Drug Administration today expanded the approved use for Eylea (aflibercept) injection to treat diabetic retinopathy in patients with Read More >
The U.S. Food and Drug Administration (FDA) has approved lenvatinib (Lenvima) to treat patients with progressive, differentiated thyroid cancer (DTC) Read More >
The European Union's (EU) Committee for Medicinal Products for Human Use (CHMP) has recommended the use of bevacizumab (Avastin) in combination with s Read More >
Anti-VEGF agent aflibercept (EYLEA®) has been approved by the European Commission for the treatment of visual impairment due to Macular Edema seconda Read More >
Dr. William Li Featured on The Dr. Oz Show

What does luck have to do with cancer? A recently published Read More >
The U.S. Food and Drug Administration today expanded the approved use for ranibizumab injection 0.3 mg (Lucentis) to treat diabetic retinopathy (DR) i Read More >


Dr. Li shares 22 Cancer Fighting Tips with Dr. Oz

Dr. William Li joins Dr. Oz to share 22 ways to cut your risk of cancer risk by 50 percent. Read More >

Dr. William Li presents at TED

Dr. William Li presents “Can we eat to starve cancer?” at TED 2010 in Long Beach, CA. Read More >




Dr. William Li and musician and activist The Edge of U2, both board members of the non-profit Angiogenesis Foundation, delivered a speech and a performance respectively to more than 200 world leading… Read More

Screen Shot 2016-02-12 at 4.15.51 PM

Ultimate Food Fight: The Angiogenesis Foundation’s Declaration of War on Cancer and Other Non-Communicable Diseases Using Diet. Read More


October 8, 2015: The non-profit Angiogenesis Foundation today launched a nationwide multimedia campaign EyeCanDoIt as their contribution to World Sight Day. Read More >


September 16, 2015: L’Angiogenesis Foundation a publié un livre blanc aujourd’hui qui aborde les besoins, les défis, ainsi que les solutions proposées au Canada pour la prévention de la perte de vision chez les diabétiques. Read More >

NPR Marketplace logo

November 6, 2014: For the second consecutive year, the Angiogenesis Foundation has received the highest rating from Charity Navigator, the prominent independent evaluator of charities. Read More >


May 20, 2014: “The Dr. Oz Show” features Dr. William Li who shares 3 all-natural breakthroughs that can reduce your risk of cancer. Read More >


April 23, 2014: The Bates-Jensen Wound Reach Foundation and the Angiogenesis Foundation announce Keith Brantly will run in the Wound Reach Foundation OUCH! Race. Read More >

DoctorOZ (1)

February 7, 2014: Dr. William Li appears on “The Dr. Oz Show” to share 22 ways to cut your cancer risk by 50%. Read More >


January 21, 2014: The Angiogenesis Foundation, in collaboration with musician / activist Peter Gabriel, has launched the Do iT Yourself Health Revolution Read More >


November 7, 2013: The Angiogenesis Foundation receives highest rating from Charity Navigator, a premiere charity evaluator, for good governance, fiscal management, accountability and transparency. Read More >


September 26, 2013: The Angiogenesis Foundation Launches Multimedia Campaigns for Saving Vision at the 13th Euretina Congress Read More >


September 26, 2013: The Angiogenesis Foundation Releases International White Paper on Improving Outcomes in the Treatment and Management of Metastatic Colorectal Cancer at the European Cancer Congress 2013 Read More >


September 26, 2013: The Angiogenesis Foundation Releases International White Paper on Advancing Treatment of Wet Age-Related Macular Degeneration at the 13th Euretina Congress Read More >


July 16, 2013: The Angiogenesis Foundation Presents Concept of Antiangiogenic Foods at IFT 2013 Annual Meeting + Food Expo Read More >


June 4, 2013: Dr. William Li discusses the impact of drug shortages for cancer patients in USA Today. Read More >



The “Best of Antiangiogenesis” is a series of webcasts, generated through Project ENABLE™, featuring presentations from leading medical experts describing research and perspectives on new angiogenesis-based therapies.

To view additional webcasts, click here




Our tea research is part of our Eat to Beat Cancer initiative, which is setting out to find foods and beverages that restore balance to the body's angiogenesis system. By purchasing this tea you are supporting our research and helping to advance the frontiers of cancer prevention.